Deterministic figures
The language model never writes figures: every number comes from the calculation and is checked before it is shown.
OVI Insights
Ask your Real World Evidence studies in plain language.
OVI answers with computed figures, charts and their methodology, always aggregated, traceable and protected by privacy controls.
From static reports to questions.
Medical societies build structured, traceable clinical registries with Latrikos. OVI Insights lets the pharmaceutical industry explore those studies with plain-language questions, without ever accessing individual data.
OVI is the Latrikos AI assistant. For each question it chooses the right analysis and runs it with deterministic statistical methods.
Ask whatever you need
- “What is Table 1 for this registry?”
- “Do patients under 65 respond better?”
- “How long until the first event?”
- “What data is there by tissue and cell type?”
- “How has prevalence changed year on year?”
OVIYour studies, in conversation
Get answers ready to use
- A headline with the finding that matters
- Tables and charts ready to present
- Findings, clinical relevance and limitations
- The next analyses, already suggested
- Save, share and export every answer
For industry
- Explore diseases and patients without waiting for a report
- Test a hypothesis before designing a study
- Access only the studies in your subscription
For the medical society
- Makes the most of its studies without handing over raw data
- Decides who accesses each study, and can revoke it
- Knows which company queries each study
- Computed figures, never invented
- Always aggregated and anonymous
- Every answer traceable to its studies
What an answer looks like.
- A headline with the most clinically relevant finding.
- A short interpretation: findings, clinical relevance and limitations.
- The figures, tables or charts behind it.
- Up to three suggested next analyses, as follow-up questions.
- The methodology, collapsed, for anyone who wants to review it.
How many patients with rheumatoid arthritis have transcriptomics, anti-TNF exposure and six-month follow-up?
142 patients meet all three criteria
- Rheumatoid arthritis1210
- + transcriptomics486
- + anti-TNF exposure231
- + follow-up ≥ 6 months142
Finding. Transcriptomics is the item that narrows the cohort most; 6 in 10 patients exposed to anti-TNF have six-month follow-up.
Limitations. Aggregated figures; follow-up is measured from the start of treatment recorded in the reports.
- Compare responders and non-responders
- Break down by tissue and cell type
- Time to flare (Kaplan-Meier)
Answers you can trust.
Privacy by default
Every result goes through a filter with k-anonymity and rounding. Small cells are hidden, and the answer says so.
Aggregated and traceable
Every answer includes the queries and studies used, and can be saved, shared and exported.
Licensed studies only
OVI only answers about the active studies included in the customer's subscription.
The analyses it knows how to run.
Descriptive statistics, frequencies, prevalence, distributions, Table 1, comparisons with confidence intervals and p-values, correlation, cross-tabulations and Kaplan-Meier curves.
Who OVI Insights is for.
Pharmaceutical companies
Answers to specific questions about diseases and patients instead of static reports, limited to the studies in their subscription.
Medical societies
They make the most of their studies without handing over raw data: they decide who accesses each study and can revoke that access.